Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price




About UroGen Pharma

UroGen Pharma (NASDAQ: URGN), fka Theracoat, is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The lead drug candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade bladder cancer and low-grade upper tract urothelial carcinoma, or UTUC. In addition, UroGen is developing two additional clinical-stage drug candidates, Vesimune, for the treatment of high-grade non-muscle invasive bladder cancer and BotuGel, for the treatment of overactive bladder and interstitial cystitis.

UroGen Pharma Headquarter Location

9 Ha’Ta’asiya St

Ra'anana, 4365007,



Latest UroGen Pharma News

UroGen Pharma to Present at Upcoming Conferences

Jan 5, 2022

January 05, 2022 08:00 AM Eastern Standard Time PRINCETON, N.J.--( BUSINESS WIRE )--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following virtual healthcare conferences in January: 40th Annual J.P. Morgan Healthcare Conference Thursday, January 13 at 9:45 a.m. ET HC Wainwright BioConnect Conference Presentation available on-demand beginning Monday, January 10 at 7:00 a.m. ET Webcasts of both the J.P. Morgan and HC Wainwright presentations will be available via the Investors section of UroGen’s website, . A replay of each webcast will be available on the Company’s website for approximately 30 days. About UroGen Pharma Ltd. UroGen is a biopharmaceutical company dedicated to building novel solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit to learn more or follow us on Twitter, @UroGenPharma. Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing UroGen Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

UroGen Pharma is included in 3 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

UroGen Pharma Patents

UroGen Pharma has filed 15 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Urinary system, Urologic procedures, Mammal male reproductive system, Implants (medicine), Medical equipment


Application Date


Grant Date



Related Topics

Urinary system, Urologic procedures, Mammal male reproductive system, Implants (medicine), Medical equipment



UroGen Pharma Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

UroGen Pharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.